Logo Image
News|Articles|January 5, 2026

4 Psychiatry Headlines You Missed in December 2025

Fact checked by: Victoria Johnson

December 2025 psychiatry updates: Teva files TEV-‘749 for schizophrenia, lumateperone boosts MDD outcomes, AGA tied to mental health, and a look back at 2025 advances.

As 2025 closed, psychiatry continued to advance with notable US Food & Drug Administration (FDA) submissions, late-stage clinical trial results, and emerging insights linking mental health to broader medical conditions. December highlighted progress in schizophrenia treatment, with Teva’s TEV- ‘749 entering the regulatory pipeline, and in major depressive disorder (MDD), as adjunctive lumateperone demonstrated rapid symptom improvement.